TESAMORELIN 10MG

Description

Tesamorelin 10mg research peptide — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

This listing is one vial of lyophilized tesamorelin at a 10mg labelled amount, supplied as research-grade material. The peptide itself is a growth hormone-releasing hormone analogue: the full 44-amino-acid human GHRH chain, amidated at the C-terminus, with a hexenoyl group fixed to the N-terminal tyrosine so that dipeptidyl peptidase-IV cannot clip it^[2]. A pharmaceutical version has been licensed since 2010 under the name Egrifta, for a single HIV-related indication^[6]; the vial sold here is a laboratory reagent, not that drug, and carries no approval for any use.

Full research overview, study table & references → Tesamorelin in Canada: research guide

Identity at a glance

This batch: certificate of analysis

Product tested	Tesamorelin 10 mg (this listing)
Testing laboratory	Janoshik Analytical (independent)
Report number	#172070
Sample received / analysed	10 June 2026 / 18 June 2026
Measured content	10.69 mg per vial (labelled 10 mg)
Purity	98.628%
Verification key	5JJD6SBIJEN2 (checkable at janoshik.com)
Report	View the report image · COA library

Two numbers matter on this report: the laboratory measured 10.69 mg of peptide in a vial labelled 10 mg, and the HPLC purity was 98.628%. Key 5JJD6SBIJEN2 can be entered on janoshik.com to confirm the document is genuine. Check the lot number on your label against the report before using it as evidence.

What researchers have looked at

• Beagle dogs (2004): an inhaled dry-powder form reached 41% of the bioavailability of a subcutaneous dose; terminal half-life 39 minutes inhaled versus 26 minutes subcutaneous^[1].
• Rat, dog and human plasma in vitro: the hexenoyl modification slowed breakdown compared with native GHRH(1–44); in pigs, rats and dogs, repeated dosing raised GH and IGF-1^[2].
• Pooled Phase III data (806 adults with HIV and excess abdominal fat): a −15.4% treatment effect on visceral fat at 26 weeks, no significant change in subcutaneous fat, and no clinically meaningful glucose change at 26 or 52 weeks^[3].
• Liver: a 50-person trial reported a modest fall in liver fat alongside visceral fat^[4]; a 61-person, 12-month trial in HIV-associated NAFLD reported a 37% relative reduction in hepatic fat fraction versus placebo, with more injection-site complaints^[5].

These are trial results for the approved medicine in defined patient groups; they are reported here as literature, not as properties of this research material, and no benefit is claimed for it.

Storage and handling

• Long-term: sealed vial at −20 °C (stated stability up to 24 months as dry powder). Short-term: cool, dry, dark. Do not freeze–thaw repeatedly.
• Once dissolved, peptides lose stability faster than as powder; prepare only what the experiment needs. No reconstitution or dosing instructions are published on this site.

Other strengths: TESAMORELIN 20MG · TESAMORELIN 5MG · Tesamorelin (Pen). Domestic shipping by Canada Post; see the shipping policy for cut-off times, delivery estimates and the free-shipping threshold. Everything else we stock is listed where you can buy peptides online in Canada.

Related reading: Tesamorelin vs Sermorelin vs CJC-1295: GHRH analogs explained

Frequently asked questions

Can I buy Tesamorelin 10mg in Canada?

Yes. The 10mg vial is stocked as research-grade lyophilized tesamorelin and shipped domestically by Canada Post, so there is no customs clearance. It is for laboratory research only and is not the licensed medicine Egrifta.

How is this Tesamorelin 10mg batch verified?

An independent Janoshik report, #172070, covers this strength: sample received 10 June 2026, analysed 18 June 2026, 10.69 mg of peptide measured against a 10 mg label, purity 98.628%, verification key 5JJD6SBIJEN2. The report is embedded above and filed in the COA library; match your lot number to it.

How should Tesamorelin 10mg be stored?

Sealed and frozen at −20 °C for long-term storage (the site states up to 24 months as lyophilized powder); cool, dry and dark if only held briefly; and never cycled repeatedly between frozen and thawed. Reconstituted solutions are less stable than the powder.

Is Tesamorelin for human use?

This vial is not. A pharmaceutical form of tesamorelin is approved for one indication in HIV-associated lipodystrophy (PMID 21668043), but the material sold here is a research reagent for laboratory use only, not for human or animal consumption, and no dosing or administration guidance is provided.

References

1. Jansen M, Darby I et al. (2004). Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm. PMID 15113616
2. Ferdinandi ES, Brazeau P et al. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. PMID 17214611
3. Falutz J, Mamputu JC et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. PMID 20554713
4. Stanley TL, Feldpausch MN et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. PMID 25038357
5. Stanley TL, Fourman LT et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. PMID 31611038
6. Dhillon S (2011). Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. PMID 21668043

For laboratory research use only. Not for human or animal consumption. This description identifies the material and its documentation and summarises published literature on the compound; it makes no claim of efficacy or safety for the material sold.